ARROWING OF BILE DUCT AFTER SURGERY FOR BILE DUCT OBSTRUCTIO
Not Applicable
- Conditions
- Health Condition 1: K831- Obstruction of bile duct
- Registration Number
- CTRI/2021/05/033813
- Lead Sponsor
- Medical College Kolkata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients who had undergone hepatico-jejunostomy for management of benign biliary diseases and willing to give written informed consent and follow study procedure.
Exclusion Criteria
1.Patients who had undergone hepatico-jejunostomy for management of malignant causes or liver transplantation.
2.Patients who didnot give written informed consent to follow study procedure.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This study is expected to find out the incidence of recurrent strictures in patients undergoing hepatico-jejunostomy for benign biliary diseases and may bring out some positive ideas regarding improvement of the quality of life of these ptients and prevention of recurrent strictures.Timepoint: 2 years
- Secondary Outcome Measures
Name Time Method To study the quality of lifeTimepoint: 2 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways contribute to early biliary stricture recurrence after hepaticojejunostomy for benign biliary disease?
How does hepaticojejunostomy compare to choledochojejunostomy in preventing biliary stricture recurrence in CTRI/2021/05/033813?
Which biomarkers correlate with postoperative biliary stricture progression in patients with K831 bile duct obstruction?
What are the long-term complications and management strategies for hepaticojejunostomy in benign biliary disease cases?
How do antifibrotic agents or immune modulators influence biliary stricture recurrence rates post-surgery for K831 obstruction?